Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","amount":"$6.8 million","upfrontCash":"Undisclosed","newsHeadline":"Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Asgard Therapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","amount":"$32.7 million","upfrontCash":"Undisclosed","newsHeadline":"Swedish Biotech Raises \u20ac30M Series A to Develop Off-the-shelf Gene Therapy for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by Asgard Therapeutics

    Menu

    Asgard Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Asgard Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Swedish Biotech Raises €30M Series A to Develop Off-the-shelf Gene Therapy for Solid Tumors

              Details:

              The financing aims to support the ongoing development of the lead program AT-108. Currently, it is being evaluated in the preclinical trial studies for the treatment of neoplasms in the form of tailored treatment.

              Lead Product(s): AT-108

              Therapeutic Area: Oncology Product Name: AT-108

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine

              Deal Size: $32.7 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing March 14, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Asgard Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Sweden
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics

              Details:

              The financing will enable Asgard Therapeutics to expand pipeline of preclinical assets and build on making personalized cancer immunotherapies optimized to unique patient. Funds will be used to further develop personalized therapy programs for multiple oncology indications.

              Lead Product(s): Off-the-shelf Gene Therapy

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Novo Holdings

              Deal Size: $6.8 million Upfront Cash: Undisclosed

              Deal Type: Financing November 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY